文献速递神经免疫

富马酸二甲酯对复发缓解型多发性硬化患者淋巴细胞的影响及临床意义

Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice.
PubMed 文献 · Neurology · 2019-03-27

该研究汇总多项富马酸二甲酯(DMF)临床试验的外周血标本,用流式细胞术量化免疫细胞亚群并随访停药后淋巴细胞计数。结果显示DMF治疗后绝对淋巴细胞计数(ALC)先下降后趋稳,记忆T/B细胞比例下降而初始细胞增加;低T细胞亚群者严重感染风险未增加,ALC与CD4+/CD8+ T细胞计数密切相关,故ALC监测仍是识别长期中重度淋巴细胞减少风险的最有效方式。

要点

  • ALC在DMF治疗中先降后稳,记忆细胞比例下降、初始细胞增加。
  • ALC与CD4+、CD8+ T细胞计数高度相关,无需常规监测淋巴细胞亚群。
  • 低T细胞亚群者严重感染风险未增加,ALC监测仍是识别长期中重度淋巴细胞减少的关键。

核心结论

  • DMF改变循环淋巴细胞亚群免疫表型,ALC与CD4+和CD8+ T细胞计数密切相关,提示无需进行淋巴细胞亚群监测以保障安全性。
  • 低T细胞亚群计数患者未观察到严重感染风险增加,ALC监测仍是识别后续发生长期中重度淋巴细胞减少(DMF治疗者进行性多灶性白质脑病的危险因素)的最有效方法。

研究设计与样本

  • 基于多项DMF临床试验的外周血标本,用流式细胞术量化免疫细胞亚群。
  • 部分患者停药后评估淋巴细胞计数,并评估包括严重感染和机会性感染在内的不良事件发生率。

主要发现

  • DMF治疗患者ALC呈先下降后稳定模式,循环功能性淋巴细胞亚群数量整体减少。
  • 循环记忆T细胞和B细胞群体相对频率下降,初始细胞增加。
  • 按ALC或T细胞亚群频率分层,DMF治疗患者严重感染或恶性肿瘤发生率均未增加。
  • 因淋巴细胞减少停用DMF的患者,停药后ALC升高,恢复时间随停药时ALC水平而异。
  • 纵向和横断面分析中T细胞亚群均与ALC密切相关。

临床怎么用

  • 临床实践中以ALC监测作为DMF治疗者安全性 vigilance 的主要手段,无需常规检测淋巴细胞亚群。
  • 对ALC降低者应关注后续发生长期中重度淋巴细胞减少的风险,该风险与进行性多灶性白质脑病相关。
  • 因淋巴细胞减少停药后应随访ALC,恢复时间因停药时ALC水平不同而异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess functional changes in lymphocyte repertoire and subsequent clinical implications during delayed-release dimethyl fumarate (DMF) treatment in patients with multiple sclerosis. METHODS: Using peripheral blood from several clinical trials of DMF, immune cell subsets were quantified using flow cytometry. For some patients, lymphocyte counts were assessed after DMF discontinuation. Incidence of adverse events, including serious and opportunistic infections, was assessed. RESULTS: In DMF-treated patients, absolute lymphocyte counts (ALCs) demonstrated a pattern of decline followed by stabilization, which also was reflected in the global reduction in numbers of circulating functional lymphocyte subsets. The relative frequencies of circulating memory T- and B-cell populations declined and naive cells increased. No increased incidence of serious infection or malignancy was observed for patients treated with DMF, even when stratified by ALC or T-cell subset frequencies. For patients who discontinued DMF due to lymphopenia, ALCs increased after DMF discontinuation; recovery time varied by ALC level at discontinuation. T-cell subsets closely correlated with ALCs in both longitudinal and cross-sectional analyses. CONCLUSIONS: DMF shifted the immunophenotype of circulating lymphocyte subsets. ALCs were closely correlated with CD4+ and CD8+ T-cell counts, indicating that lymphocyte subset monitoring is not required for safety vigilance. No increased risk of serious infection was observed in patients with low T-cell subset counts. Monitoring ALC remains the most effective way of identifying patients at risk of subsequently developing prolonged moderate to severe lymphopenia, a risk factor for progressive multifocal leukoencephalopathy in DMF-treated patients. TRIAL REGISTRATION NUMBERS: EUDRA CT 2015-001973-42, NCT00168701, NCT00420212, NCT00451451, and NCT00835770.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Mehta D, Miller C, Arnold DL, et al. Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice. Neurology. 2019. PMID: 30918100. doi:10.1212/WNL.0000000000007262

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。